2022-12-13-世界卫生组织-Multi-country_outbreak_of_mpox,_External_situation_report_12-_14_December_2022_13页_761kb

报告摘要

Multi-country mpox Outbreak Summary

Global Epidemiological Overview

From 1 January to 11 December 2022, 82,624 laboratory-confirmed mpox cases and 65 deaths were reported globally across 110 countries. Since the last report on 1 December, 1,517 new cases (1.9% increase) and 10 deaths were recorded. The weekly case decline was 46%, with marked drops in the Americas (-47%) and European Region (-14%). The top 10 countries accounted for 86% of cases: USA, Brazil, Spain, France, Colombia, UK, Germany, Peru, Mexico, and Canada.

Risk Assessment and Regional Breakdown

Risk levels: Americas - high, African Region - moderate, Southeast Asia and Western Pacific - low.
Regional details: Americas had the highest cases (55,722) and deaths (44); European Region followed with 25,581 cases and 5 deaths.
Stable or declining trends: Most countries with no cases in over 21 days.

Epidemiology and Transmission

Demographics: 96.8% of cases were men (median age 34 years), with high concentration among gay, bisexual, and other men who have sex with men (85.9% of reported cases). Transmission was primarily sexual, accounting for 72.7% of events.
Other findings: Outbreak intersects with HIV/STI syndemics; cases in Africa show animal-to-human transmission; 46% of deaths occurred in the Americas.

Responses and Missions

Field support: WHO missions to Nigeria (Oct 2022) and Central African Republic (Nov 2022) to strengthen surveillance, labs, and clinical management.
Global actions: 20 countries expressed interest in tecovirimat for emergency use; technical briefings and webinars provided guidance on prevention, control, and stigma reduction.

Technical Guidance and Recommendations

WHO issued interim guidance on vaccines, surveillance, clinical management, and risk communication.
Partners issued statements recommending new name "mpox"; emphasis on sexual health focus, integrating mpox with HIV/STI services, and ensuring equitable access to resources.
Data caveats noted: Variability in reporting, case definitions, and delays.

Key Outcomes

Acknowledged stabilization but stressed ongoing risks; behavior changes and immunity may contribute to declines, but origins unclear.
Call for sustained efforts on community engagement, surveillance intensity, and research to address disparities in outbreak response worldwide.

展开完整摘要